Affiliation:
1. Lovely Professional University,Department of Microbiology,Phagwara,India,144411,|Federal University Dutse,Department of Microbiology and Biotechnology,Nigeria,
2. Lovely Professional University,Department of Microbiology,Phagwara,India,144411,
Abstract
Drug discovery and development is a complex and lengthy process aimed at producing therapeutic substances that can be both effective in terms of pharmacological activity, specificity, good affinity to its target molecule, and safe for humans. It is a necessary step due to many emerging diseases of microbial, parasitic and genetic diseases affecting the entire world so that effective prophylaxis and treatment could be provided. The successful process of discovering a new drug relies on proper discovery and characterization of the lead compound followed by the preclinical studies that ascertain the safety and efficacy of the newly discovered compound. A number of information gathered from preclinical studies that, include information about the formulation, dosage, delivery, pharmacokinetic, pharmacodynamic, mode of action of the drug as well as its relation with other drugs when they interacted, could determine the fate of the new drug’s approval by the regulatory agency for a clinical trial on humans. Human clinical trials with the new drug under investigation are carried out on volunteers in different phases with a common goal to ascertain the new drug's safety, efficacy, and possible side effect in the actual environment. Since the human body is more dynamic, optimal dosage and effect of other substances on the drug itself are determined so as to ensure better treatment; satisfactory results from the human trial could pave the way for application and approval for a human trial in phase IV where the drug may subsequently go for commercialization but with strict monitoring for any unforeseen side effect most especially in a vulnerable group. Although this is an expensive, tedious and risky process for the pharmaceutical industry and volunteers, which takes many years, it is necessary. This chapter discusses the necessary steps for developing a new drug from the initial discovery from bench-top up to human trial and commercialization as an over-the-counter drug. <br>
Publisher
BENTHAM SCIENCE PUBLISHERS
Reference149 articles.
1. Wu Y-S.; Lin W-H.; Hsu J.T.; Hsieh H.P.; Antiviral drug discovery against SARS-CoV. Curr Med Chem 2006,13(17),2003-2020
2. Tan E.L.C.; Ooi E.E.; Lin C.Y.; Tan H.C.; Ling A.E.; Lim B.; Stanton L.W.; Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004,10(4),581-586
3. Holmes K.K.; Bertozzi S.; Bloom B.R.; Major infectious diseases: Key messages from disease control priorities. In: Major Infectious Diseases: Disease Control Priorities (Volume 6), 3 ed. The World Bank 2017,1-27
4. Brady M.T.; Oleske J.M.; Williams P.L.; Elgie C.; Mofenson L.M.; Dankner W.M.; Van Dyke R.B.; Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010,53(1),86-94
5. Sloan D.; Davies G.; Khoo S.; Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev 2013,9(3),200-210